Coverart for item
The Resource Formulating poorly water soluble drugs, Robert O. Williams III, Alan B. Watts, Dave A. Miller, editors

Formulating poorly water soluble drugs, Robert O. Williams III, Alan B. Watts, Dave A. Miller, editors

Label
Formulating poorly water soluble drugs
Title
Formulating poorly water soluble drugs
Statement of responsibility
Robert O. Williams III, Alan B. Watts, Dave A. Miller, editors
Contributor
Editor
Subject
Language
eng
Member of
Cataloging source
GW5XE
Dewey number
615.1/9
Illustrations
illustrations
Index
index present
LC call number
RM301.25
LC item number
.F67 2016eb
Literary form
non fiction
Nature of contents
  • dictionaries
  • bibliography
http://library.link/vocab/relatedWorkOrContributorDate
  • 1956-
  • 1981-
http://library.link/vocab/relatedWorkOrContributorName
  • Williams, Robert O.
  • Watts, Alan B.
  • Miller, Dave A.
Series statement
AAPS advances in pharmaceutical sciences series,
Series volume
volume 22
http://library.link/vocab/subjectName
  • Drug development
  • Drugs
  • Drug Compounding
  • Biological Availability
  • Chemical Phenomena
  • Chemistry, Pharmaceutical
  • Drug Design
Label
Formulating poorly water soluble drugs, Robert O. Williams III, Alan B. Watts, Dave A. Miller, editors
Instantiates
Publication
Antecedent source
unknown
Bibliography note
Includes bibliographical references and index
Carrier category
online resource
Carrier category code
  • cr
Carrier MARC source
rdacarrier
Color
multicolored
Content category
text
Content type code
  • txt
Content type MARC source
rdacontent
Contents
  • Dedication; Preface; Contents; Contributors; Chapter 1: Route-Specific Challenges in the Delivery of Poorly Water-Soluble Drugs; 1.1 Introduction; 1.2 Oral Route of Administration; 1.2.1 Challenges in Oral Delivery of Poorly Water-Soluble Drugs; 1.3 Parenteral Route of Administration; 1.3.1 Challenges in Parenteral Delivery of Poorly Water-­Soluble Drugs; 1.4 Ocular Route of Administration; 1.4.1 Challenges in Ocular Delivery of Poorly Water-Soluble Drugs; 1.5 Nasal Route of Administration; 1.5.1 Challenges in Nasal Delivery of Poorly Water-Soluble Drugs; 1.6 Pulmonary Route of Administration
  • 1.6.1 Challenges in Pulmonary Delivery of Poorly Water-­Soluble Drugs1.7 Summary; References; Chapter 2: Optimizing the Formulation of Poorly Water-­Soluble Drugs; 2.1 Introduction; 2.1.1 Solubility Studies; 2.1.1.1 Solubility Prediction; 2.1.2 Experimental Aqueous Solubility Determination; 2.1.3 pH-Solubility Profiles; 2.1.4 Intrinsic Dissolution; 2.1.4.1 Compact Preparation; 2.1.4.2 Intrinsic Dissolution Testing; 2.2 Solid-State Characterization; 2.2.1 Thermal Analysis; 2.2.1.1 Differential Scanning Calorimetry; 2.2.1.2 Flory-Huggins; 2.2.1.3 Thermogravimetric Analysis
  • 2.2.2 Fourier Transform Infrared Spectroscopy2.2.2.1 Sample Preparation; 2.2.2.2 Polymorph Screening; 2.2.2.3 Excipient Interactions; 2.2.3 X-Ray Diffraction; 2.2.3.1 Parameter Selection; 2.2.3.2 Polymorph Screening; 2.2.3.3 Excipient Interactions; 2.2.3.4 Pair Distribution Function (PDF); 2.2.4 Specific Surface Area; 2.2.4.1 BET Surface Area Analysis; 2.2.5 Solid-State Nuclear Magnetic Resonance (SSNMR); 2.2.6 Residual Solvent Analysis; 2.2.6.1 Residual Solvent Guidelines; 2.2.6.2 Analytical Determination of Residual Solvent Levels; 2.3 Stability Testing; 2.3.1 Stability Monitoring
  • 2.3.2 Chemical Stability2.3.3 Stability Testing Conditions; 2.4 Dissolution Testing; 2.4.1 Dissolution Studies; 2.4.1.1 Sample Handling; 2.4.1.2 Excipient Screening for Supersaturation Maintenance Ability; 2.4.1.3 Supersaturation Dissolution Studies; 2.4.1.4 Alternative Dissolution Studies; 2.4.2 In Vivo Testing; 2.4.2.1 Administration Via Inhalation; 2.4.2.2 Oral Administration; 2.5 Conclusions; References; Chapter 3: Solid-State Techniques for Improving Solubility; 3.1 Introduction; 3.2 Pharmaceutical Salts; 3.2.1 Pharmaceutical Salt Selection; 3.2.2 Solubility Enhancement
  • 3.3 Polymorphs and Amorphous Forms3.3.1 Polymorph Preparation; 3.3.2 Amorphous Form Preparation; 3.3.3 Thermodynamics of Metastable Solids; 3.3.4 Solubility and Bioavailability Enhancement; 3.4 Pharmaceutical Co-crystals; 3.4.1 Co-crystal Preparation; 3.4.2 Solubility of Co-crystals; 3.5 Summary; References; Chapter 4: Mechanical Particle-Size Reduction Techniques; 4.1 Introduction; 4.2 Rationale Behind the Reduction of Particle-Size; 4.3 Milling; 4.3.1 Dry Milling; 4.3.1.1 Fluidized Bed Jet Milling; 4.3.1.2 Spiral Jet "Pancake" Mill; 4.3.1.3 Pin Mill
Dimensions
unknown
Edition
Second edition.
Extent
1 online resource (xiv, 779 pages)
File format
unknown
Form of item
online
Isbn
9783319426099
Level of compression
unknown
Media category
computer
Media MARC source
rdamedia
Media type code
  • c
Other control number
10.1007/978-3-319-42609-9
Other physical details
illustrations.
Quality assurance targets
not applicable
Reformatting quality
unknown
Sound
unknown sound
Specific material designation
remote
System control number
  • SPR966446900
  • ocn966446900
Label
Formulating poorly water soluble drugs, Robert O. Williams III, Alan B. Watts, Dave A. Miller, editors
Publication
Antecedent source
unknown
Bibliography note
Includes bibliographical references and index
Carrier category
online resource
Carrier category code
  • cr
Carrier MARC source
rdacarrier
Color
multicolored
Content category
text
Content type code
  • txt
Content type MARC source
rdacontent
Contents
  • Dedication; Preface; Contents; Contributors; Chapter 1: Route-Specific Challenges in the Delivery of Poorly Water-Soluble Drugs; 1.1 Introduction; 1.2 Oral Route of Administration; 1.2.1 Challenges in Oral Delivery of Poorly Water-Soluble Drugs; 1.3 Parenteral Route of Administration; 1.3.1 Challenges in Parenteral Delivery of Poorly Water-­Soluble Drugs; 1.4 Ocular Route of Administration; 1.4.1 Challenges in Ocular Delivery of Poorly Water-Soluble Drugs; 1.5 Nasal Route of Administration; 1.5.1 Challenges in Nasal Delivery of Poorly Water-Soluble Drugs; 1.6 Pulmonary Route of Administration
  • 1.6.1 Challenges in Pulmonary Delivery of Poorly Water-­Soluble Drugs1.7 Summary; References; Chapter 2: Optimizing the Formulation of Poorly Water-­Soluble Drugs; 2.1 Introduction; 2.1.1 Solubility Studies; 2.1.1.1 Solubility Prediction; 2.1.2 Experimental Aqueous Solubility Determination; 2.1.3 pH-Solubility Profiles; 2.1.4 Intrinsic Dissolution; 2.1.4.1 Compact Preparation; 2.1.4.2 Intrinsic Dissolution Testing; 2.2 Solid-State Characterization; 2.2.1 Thermal Analysis; 2.2.1.1 Differential Scanning Calorimetry; 2.2.1.2 Flory-Huggins; 2.2.1.3 Thermogravimetric Analysis
  • 2.2.2 Fourier Transform Infrared Spectroscopy2.2.2.1 Sample Preparation; 2.2.2.2 Polymorph Screening; 2.2.2.3 Excipient Interactions; 2.2.3 X-Ray Diffraction; 2.2.3.1 Parameter Selection; 2.2.3.2 Polymorph Screening; 2.2.3.3 Excipient Interactions; 2.2.3.4 Pair Distribution Function (PDF); 2.2.4 Specific Surface Area; 2.2.4.1 BET Surface Area Analysis; 2.2.5 Solid-State Nuclear Magnetic Resonance (SSNMR); 2.2.6 Residual Solvent Analysis; 2.2.6.1 Residual Solvent Guidelines; 2.2.6.2 Analytical Determination of Residual Solvent Levels; 2.3 Stability Testing; 2.3.1 Stability Monitoring
  • 2.3.2 Chemical Stability2.3.3 Stability Testing Conditions; 2.4 Dissolution Testing; 2.4.1 Dissolution Studies; 2.4.1.1 Sample Handling; 2.4.1.2 Excipient Screening for Supersaturation Maintenance Ability; 2.4.1.3 Supersaturation Dissolution Studies; 2.4.1.4 Alternative Dissolution Studies; 2.4.2 In Vivo Testing; 2.4.2.1 Administration Via Inhalation; 2.4.2.2 Oral Administration; 2.5 Conclusions; References; Chapter 3: Solid-State Techniques for Improving Solubility; 3.1 Introduction; 3.2 Pharmaceutical Salts; 3.2.1 Pharmaceutical Salt Selection; 3.2.2 Solubility Enhancement
  • 3.3 Polymorphs and Amorphous Forms3.3.1 Polymorph Preparation; 3.3.2 Amorphous Form Preparation; 3.3.3 Thermodynamics of Metastable Solids; 3.3.4 Solubility and Bioavailability Enhancement; 3.4 Pharmaceutical Co-crystals; 3.4.1 Co-crystal Preparation; 3.4.2 Solubility of Co-crystals; 3.5 Summary; References; Chapter 4: Mechanical Particle-Size Reduction Techniques; 4.1 Introduction; 4.2 Rationale Behind the Reduction of Particle-Size; 4.3 Milling; 4.3.1 Dry Milling; 4.3.1.1 Fluidized Bed Jet Milling; 4.3.1.2 Spiral Jet "Pancake" Mill; 4.3.1.3 Pin Mill
Dimensions
unknown
Edition
Second edition.
Extent
1 online resource (xiv, 779 pages)
File format
unknown
Form of item
online
Isbn
9783319426099
Level of compression
unknown
Media category
computer
Media MARC source
rdamedia
Media type code
  • c
Other control number
10.1007/978-3-319-42609-9
Other physical details
illustrations.
Quality assurance targets
not applicable
Reformatting quality
unknown
Sound
unknown sound
Specific material designation
remote
System control number
  • SPR966446900
  • ocn966446900

Library Locations

Processing Feedback ...